ClinicalTrials.gg

Program

Stem Cell

Also written as “Stem cells”, “Single Dose MPCs Injection” and “Autologous Bone Marrow CD34+ Stem Cells”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Myocardial Infarction · Retinal Vein Occlusion · Coronary Artery Disease · Anemia, Sickle Cell, led by 10 companies.

Furthest: phase 2, since Aug 6, 201913 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Honya Medical21 open or runningphase 2since Aug 6, 2019Aug 6, 2019none ahead
Kang Stem Biotech20 open or runningphase 2since Nov 7, 2013Nov 7, 2013none ahead
SMSbiotech22 open or runningphase 2since Sep 22, 2026Mar 13, 2025Dec 2026phase 1 · NCT06986070
AlloCure10 open or runningphase 2since May 17, 2012May 17, 2012none ahead
BRL Medicine11 open or runningno phasesince Feb 23, 2024Feb 23, 2024none ahead
Mesoblast10 open or runningphase 2since Feb 3, 2011Feb 3, 2011none ahead
StemCells10 open or runningphase 1since Nov 5, 2010Nov 5, 2010none ahead
Stemedica Cell Technologies10 open or runningphase 2since Jan 14, 2013Jan 14, 2013none ahead
Stempeutics Research Pvt10 open or runningphase 2since Apr 17, 2009Apr 17, 2009none ahead
The Emmes10 open or runningphase 2since Jun 6, 2019Jun 6, 2019none ahead

Also a collaborator on its studies: cardiocell-llc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 17, 2009First study: phase 2 study in Myocardial InfarctionNew to Stempeutics Research PvtStempeutics Research Pvt · NCT00883727 · 20 enrolled · India
  2. Nov 5, 2010StemCells's first study: phase 1 study in Neuronal Ceroid-LipofuscinosesNew to StemCellsStemCells · NCT01238315 · United States
  3. Feb 3, 2011Mesoblast's first study: phase 2 study in Intervertebral Disc DegenerationNew to MesoblastMesoblast · NCT01290367 · 100 enrolled · United States, Australia
  4. May 17, 2012AlloCure's first study: phase 2 study in Acute Kidney InjuryNew to AlloCureAlloCure · NCT01602328 · 156 enrolled · United States, Canada
  5. Jan 14, 2013Stemedica Cell Technologies's first study: phase 2 study in ST Elevation Myocardial InfarctionNew to Stemedica Cell TechnologiesStemedica Cell Technologies · NCT01770613 · United States
  6. Nov 7, 2013Kang Stem Biotech's first study: phase 2 study in Crohn DiseaseNew to Kang Stem BiotechKang Stem Biotech · NCT02000362 · 24 enrolled · Korea, Republic of
  7. Sep 27, 2016Phase 1 study in PsoriasisKang Stem Biotech · NCT02918123 · 9 enrolled · Korea, Republic of
  8. Jun 6, 2019The Emmes's first study: phase 2 study in Retinal Vein OcclusionNew to The EmmesThe Emmes · NCT03981549 · 16 enrolled · United States
  9. Aug 6, 2019Honya Medical's first study: phase 1 study in Coronary Artery DiseaseNew to Honya MedicalHonya Medical · NCT04052191 · 40 planned · Taiwan
  10. Aug 6, 2019Phase 2 study in Myocardial InfarctionHonya Medical · NCT04050163 · 11 enrolled · Taiwan
  11. Feb 23, 2024BRL Medicine's first study: no phase study in Anemia, Sickle CellNew to BRL MedicineBRL Medicine · NCT06287086 · 1 planned
  12. Mar 13, 2025SMSbiotech's first study: phase 1 study in Pulmonary Disease, Chronic ObstructiveNew to SMSbiotechSMSbiotech · NCT06986070 · 18 planned · Australia
  13. Sep 22, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructivePhase 2 reachedSMSbiotech · NCT07871890 · 125 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 1 study in Pulmonary Disease, Chronic ObstructiveSMSbiotech · NCT06986070
  2. Oct 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveSMSbiotech · NCT07871890

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07871890Pulmonary Disease, Chronic Obstructive · United States2Not yet recruitingSMSbiotechOct 2027125
NCT06986070Pulmonary Disease, Chronic Obstructive · Australia1RecruitingSMSbiotechDec 202618
NCT06287086Anemia, Sickle Cell–Not yet recruitingBRL MedicineAug 20, 20251
NCT04052191Coronary Artery Disease · Taiwan1Not yet recruitingHonya MedicalJan 1, 202640
NCT04050163Myocardial Infarction · Taiwan2CompletedHonya MedicalMay 4, 202311
NCT03981549Retinal Vein Occlusion · United States2CompletedThe EmmesNov 7, 202316
NCT02918123Psoriasis · Korea, Republic of1UNKNOWNKang Stem BiotechDec 20219
NCT02000362Crohn Disease · Korea, Republic of2UNKNOWNKang Stem BiotechSep 201824
NCT01770613ST Elevation Myocardial Infarction · United States2WithdrawnStemedica Cell TechnologiesMay 20160
NCT01602328Acute Kidney Injury · United States, Canada2TerminatedAlloCureJun 2014156
NCT01290367Intervertebral Disc Degeneration · United States, Australia2CompletedMesoblastJul 2013100
NCT01238315Neuronal Ceroid-Lipofuscinoses · United States1WithdrawnStemCellsApr 20110
NCT00883727Myocardial Infarction · India2CompletedStempeutics Research PvtMay 201020

How it is read

Names in the registry

  • “Stem cells”, 4 entries
  • “Single Dose MPCs Injection”, 2 entries
  • “Autologous Bone Marrow CD34+ Stem Cells”, 1 entry
  • “MCRcI® stem cells”, 1 entry
  • “BRL-101 autologous hematopoietic stem and progenitor cells injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.